Want to see SION full AI Analyst Report?
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:47Neutral
Price Target:
$42.00
▼(-3.54% Downside)
Action:Reiterated
Date:06/19/26
The score is primarily held back by weak financial performance (pre-revenue with widening losses and significant ongoing cash burn), partially offset by a stronger, low-leverage balance sheet. Technical indicators also lean negative with price below key moving averages and a negative MACD, while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
A materially stronger 2025 balance sheet with positive equity and very low leverage reduces near-term solvency risk and expands strategic flexibility. This durable capital base provides runway and bargaining power for partnering, licensing, or staged financings while clinical programs progress.
Negative Factors
Pre-revenue with widening losses
Persistent pre-revenue status and materially larger net losses reflect sustained spending without offsetting sales. Over a multi-month horizon this necessitates external funding, increases dilution risk, and constrains ability to expand programs or accelerate timelines absent successful financing or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A materially stronger 2025 balance sheet with positive equity and very low leverage reduces near-term solvency risk and expands strategic flexibility. This durable capital base provides runway and bargaining power for partnering, licensing, or staged financings while clinical programs progress.
Read all positive factors
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.90B
Dividend YieldN/A
Average Volume (3M)397.51K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS Growth-27.48%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume390,796
30 Day Avg. Volume397,515
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.54K
Enterprise Value/Ebitda-19.78
Forecast
1Y Price Target
$51.71Price Target Upside18.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal funct...
How the Company Makes Money
null...
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -453.00K | -647.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -81.06M | -74.62M | -61.02M | -46.68M | -40.12M |
| Net Income | -85.56M | -75.27M | -61.69M | -47.26M | -40.24M |
Balance Sheet | |||||
| Total Assets | 305.04M | 325.95M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 216.15M | 235.88M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.38M | 8.68M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 16.83M | 19.12M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 288.21M | 306.83M | -163.71M | -114.88M | -69.92M |
Cash Flow | |||||
| Free Cash Flow | -72.14M | -66.67M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -71.85M | -66.30M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | 47.27M | -118.75M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 5.21M | 205.71M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Risk Analysis
Sionna Therapeutics, Inc. disclosed 76 risk factors in its most recent earnings report. Sionna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.69B | -3.32 | -53.31% | ― | 213.96% | 25.74% | |
58 Neutral | $5.12B | -39.23 | -41.54% | ― | 39.04% | 32.40% | |
58 Neutral | $1.98B | -12.64 | -55.68% | ― | ― | 51.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.90B | -22.26 | -27.31% | ― | ― | -27.48% | |
45 Neutral | $1.99B | -11.45 | -48.84% | ― | -83.20% | -439.48% | |
44 Neutral | $1.28B | -4.90 | -45.27% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
SION
Sionna Therapeutics, Inc.
42.97
25.62
147.67%
STOK
Stoke Therapeutics
32.39
21.04
185.37%
VIR
Vir Biotechnology
10.38
5.34
105.95%
IMTX
Immatics
9.56
4.18
77.70%
TNGX
Tango Therapeutics
32.56
27.44
535.94%
AMLX
Amylyx Pharmaceuticals Inc
18.70
12.29
191.73%
Sionna Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor
Positive
Jun 18, 2026
At its June 17, 2026 Annual Meeting of Stockholders, Sionna Therapeutics, Inc. reported that a quorum was present, with 45,142,330 common shares outstanding as of the April 21, 2026 record date, and stockholders voted on the election of four Class...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.